• Mashup Score: 0

    The Food and Drug Administration Amendments Act of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a d rug or biological product outweigh its risks. The table below provides links to currently approved individual and shared system REMS. Information on historical and released REMS is available in downloadable: data files. Abecma (Idecabtagene vicleucel), suspension, for intravenous infusion BLA #125736 Idecabtagene

    Tweet Tweets with this article
    • @BonumCe @Global_CME @ACCCBuzz @umangtalking @JungSongCNS @jaiyesi1 @AlexSpiraMDPhD @killthecancer @KBollinMD @BSantomasso 6/Step 1️⃣Review FDA REMS program 🔗https://t.co/et2DRbxxFl 🔑REMS requirements are met by accreditation w/ @FACTcelltherapy 🔑 #CART (idecabtagene vicleucel & ciltacabtagene autoleucel) are admin'd in a cellular therapy center capable of apheresis #MMsm #MultipleMyeloma https://t.co/O26vQk1xbL

  • Mashup Score: 0

    – New Search Back To Search Results Device Classification Name alternate controller enabled insulin infusion pump 510(k) Number K213536 Device…

    Tweet Tweets with this article
    • On Tuesday, July 25, we cleared for marketing the DEKA ACE Pump System, an Alternate Controller Enabled insulin pump that delivers insulin under the skin for people 13 years of age and older with diabetes mellitus. https://t.co/I08uTurGiE